• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Demeclocycline therapy for resistant oedema in advanced cardiac failure.地美环素治疗晚期心力衰竭的难治性水肿
Postgrad Med J. 1980 Feb;56(652):121-3. doi: 10.1136/pgmj.56.652.121.
2
Refractory oedema in congestive heart failure: a contributory role of loop diuretics?充血性心力衰竭中的难治性水肿:襻利尿剂的促成作用?
J Intern Med. 1995 Feb;237(2):211-4. doi: 10.1111/j.1365-2796.1995.tb01163.x.
3
Demeclocycline treatment of water retention in congestive heart failure.去甲金霉素治疗充血性心力衰竭中的水潴留
Br Med J. 1978 Mar 25;1(6115):760. doi: 10.1136/bmj.1.6115.760.
4
Combination diuretic treatment in severe heart failure: a randomised controlled trial.重度心力衰竭的联合利尿剂治疗:一项随机对照试验。
Br Heart J. 1994 Feb;71(2):146-50. doi: 10.1136/hrt.71.2.146.
5
Combination of furosemide and metolazone in the treatment of severe congestive heart failure.速尿与美托拉宗联合治疗重度充血性心力衰竭
Isr J Med Sci. 1986 Nov;22(11):787-90.
6
Mannitol and frusemide in the treatment of diuretic resistant oedema in nephrotic syndrome.甘露醇和速尿治疗肾病综合征中利尿剂抵抗性水肿
Arch Dis Child. 1999 Feb;80(2):184-5. doi: 10.1136/adc.80.2.184.
7
Metolazone and its role in edema management.
Congest Heart Fail. 2003 Mar-Apr;9(2):100-5. doi: 10.1111/j.1527-5299.2003.01907.x.
8
Clinical experience with metolazone--a new diuretic--in cases of edema and ascites due to hepatic cirrhosis, C.C.F., and malnutrition.美托拉宗(一种新型利尿剂)用于肝硬化、充血性心力衰竭及营养不良所致水肿和腹水的临床经验。
J Postgrad Med. 1977 Oct;23(4):147-55.
9
Diuretics in congestive heart failure.充血性心力衰竭中的利尿剂
Cardiol Clin. 1989 Feb;7(1):87-97.
10
Metolazone in treatment of severe refractory congestive cardiac failure.美托拉宗治疗重度难治性充血性心力衰竭
Lancet. 1990 Jan 6;335(8680):29-31. doi: 10.1016/0140-6736(90)90148-x.

本文引用的文献

1
Effects of demethylchlortetracycline on cellular action of antidiuretic hormone in vitro.
Kidney Int. 1974 Apr;5(4):279-84. doi: 10.1038/ki.1974.37.
2
Demeclocycline-induced nephrogenic diabetes insipidus. In-vivo and in-vitro studies.
Ann Intern Med. 1973 Nov;79(5):679-83. doi: 10.7326/0003-4819-79-5-679.
3
Renal chloride transport and diuretics.肾脏氯离子转运与利尿剂
Circulation. 1976 Apr;53(4):587-8. doi: 10.1161/01.cir.53.4.587.
4
Letter: Demeclocycline treatment of water retention in cirrhosis.信件:去甲金霉素治疗肝硬化腹水潴留
Ann Intern Med. 1976 Sep;85(3):336-7. doi: 10.7326/0003-4819-85-3-336.
5
Demeclocycline in congestive cardiac failure.去甲金霉素与充血性心力衰竭
Br Med J. 1978 May 13;1(6122):1282. doi: 10.1136/bmj.1.6122.1282-a.
6
Demeclocycline treatment of water retention in congestive heart failure.去甲金霉素治疗充血性心力衰竭中的水潴留
Br Med J. 1978 Mar 25;1(6115):760. doi: 10.1136/bmj.1.6115.760.
7
Renal failure associated with demeclocycline in cirrhosis.
Ann Intern Med. 1977 Aug;87(2):195-7. doi: 10.7326/0003-4819-87-2-195.
8
Demeclocycline and therapy of hyponatremia.
Ann Intern Med. 1977 Jan;86(1):113-4. doi: 10.7326/0003-4819-86-1-113.

地美环素治疗晚期心力衰竭的难治性水肿

Demeclocycline therapy for resistant oedema in advanced cardiac failure.

作者信息

Bonser R S, Ghose R R

出版信息

Postgrad Med J. 1980 Feb;56(652):121-3. doi: 10.1136/pgmj.56.652.121.

DOI:10.1136/pgmj.56.652.121
PMID:6771750
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2425516/
Abstract

A patient with long-standing ischaemic heart disease and severe low output congestive cardiac failure received numerous diuretics, which gradually became ineffective. Resistant oedema was treated by adding demeclocycline to the current diuretic regime of frusemide and metolazone. Diuresis resulted, oedema disappeared and body weight fell. This drug combination was continued without complication for a further 6 months until his death.

摘要

一位患有长期缺血性心脏病和严重低输出量充血性心力衰竭的患者接受了多种利尿剂治疗,但这些利尿剂逐渐失效。通过在当前使用速尿和美托拉宗的利尿方案中添加地美环素,治疗顽固性水肿。利尿作用产生,水肿消失,体重下降。这种药物组合持续使用6个月无并发症,直至患者死亡。